- Home
- CGNT vs LXEO Comparison
CGNT vs LXEO Comparison
Compare CGNT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- LXEO
- Stock Information
- Founded
- CGNT 2020
- LXEO 2017
- Country
- CGNT Israel
- LXEO United States
- Employees
- CGNT N/A
- LXEO N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- LXEO
- Sector
- CGNT Technology
- LXEO
- Exchange
- CGNT Nasdaq
- LXEO Nasdaq
- Market Cap
- CGNT 618.0M
- LXEO 597.8M
- IPO Year
- CGNT N/A
- LXEO 2023
- Fundamental
- Price
- CGNT $8.24
- LXEO $9.64
- Analyst Decision
- CGNT Buy
- LXEO Strong Buy
- Analyst Count
- CGNT 2
- LXEO 9
- Target Price
- CGNT $14.00
- LXEO $18.22
- AVG Volume (30 Days)
- CGNT 244.9K
- LXEO 1.4M
- Earning Date
- CGNT 12-09-2025
- LXEO 11-05-2025
- Dividend Yield
- CGNT N/A
- LXEO N/A
- EPS Growth
- CGNT N/A
- LXEO N/A
- EPS
- CGNT N/A
- LXEO N/A
- Revenue
- CGNT $376,566,000.00
- LXEO N/A
- Revenue This Year
- CGNT $15.30
- LXEO N/A
- Revenue Next Year
- CGNT $11.30
- LXEO N/A
- P/E Ratio
- CGNT N/A
- LXEO N/A
- Revenue Growth
- CGNT 14.04
- LXEO N/A
- 52 Week Low
- CGNT $7.64
- LXEO $1.45
- 52 Week High
- CGNT $11.66
- LXEO $10.38
- Technical
- Relative Strength Index (RSI)
- CGNT 47.86
- LXEO 58.68
- Support Level
- CGNT $7.87
- LXEO $8.75
- Resistance Level
- CGNT $8.49
- LXEO $10.11
- Average True Range (ATR)
- CGNT 0.23
- LXEO 0.63
- MACD
- CGNT -0.03
- LXEO 0.01
- Stochastic Oscillator
- CGNT 45.88
- LXEO 82.04
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.